Answers are grounded in this paper and cite their sources.
Background Bardet-Biedl syndrome (BBS) is a rare autosomal recessive ciliopathy characterized by rod-cone dystrophy, obesity, postaxial polydactyly, renal dysfunction, genital anomalies, and intellectual disability. Genital anomalies occur in 59–98% of patients; vaginal atresia is one of the most common genital tract anomalies in females with BBS and may present prenatally as hydrometrocolpos or, after puberty, as hematometrocolpos with cyclic pain and pelvic mass. Vaginoplasty is a preferred surgical option for symptom relief and fertility preservation; however, it requires long-term postoperative stenting and dilation. In BBS patients with intellectual disability, the feasibility and sustainability of such care must be assessed individually. Evidence on the management of adolescent BBS with vaginal atresia remains limited to case reports. Case presentation We report a 13-year-old girl with BBS10-related BBS and intellectual disability who presented with recurrent hematometrocolpos secondary to complete vaginal re-atresia. Vaginoplasty performed in infancy for hydrometrocolpos had failed because postoperative vaginal dilation was discontinued. After counseling, her parents, as legal guardians, chose hysterectomy over secondary vaginoplasty. The patient recovered well at the 1-year follow-up. Conclusions Secondary vaginoplasty was not considered feasible for this patient because the surgery would be difficult, postoperative complications would be difficult to control, and long-term vaginal dilation and related care could not be reliably maintained. Hysterectomy was chosen to relieve obstruction, not for sterilization. After full disclosure, her parents as legal guardians decided based on the patient’s best interests, with disability itself, sexual assault risk, and genetic risk explicitly excluded as indications. This case supports individualized risk–benefit assessment rather than routine anatomical reconstruction; the conclusion is patient-specific and should not be generalized. Clinical Trial Number Not applicable
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: